JPMorgan Chase & Co. Sells 577,428 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

JPMorgan Chase & Co. trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 93.5% in the third quarter, Holdings Channel.com reports. The firm owned 39,834 shares of the biotechnology company’s stock after selling 577,428 shares during the quarter. JPMorgan Chase & Co.’s holdings in Ascendis Pharma A/S were worth $5,948,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ASND. Loomis Sayles & Co. L P boosted its holdings in shares of Ascendis Pharma A/S by 35.3% in the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock valued at $27,566,000 after buying an additional 48,120 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after acquiring an additional 4,338 shares in the last quarter. Evolutionary Tree Capital Management LLC boosted its stake in Ascendis Pharma A/S by 82.3% in the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after purchasing an additional 11,223 shares during the period. Valence8 US LP bought a new position in Ascendis Pharma A/S during the 3rd quarter worth about $685,000. Finally, Nomura Asset Management Co. Ltd. raised its stake in shares of Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock valued at $2,688,000 after purchasing an additional 5,371 shares during the period.

Ascendis Pharma A/S Trading Down 2.4 %

NASDAQ ASND opened at $131.62 on Friday. The firm has a market capitalization of $7.99 billion, a P/E ratio of -16.29 and a beta of 0.65. The firm’s fifty day moving average price is $132.95 and its two-hundred day moving average price is $133.55. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00.

Analyst Ratings Changes

Several research analysts have recently weighed in on ASND shares. TD Cowen reduced their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. JPMorgan Chase & Co. reduced their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus raised their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, Bank of America increased their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.